Defective signaling of vascular endothelial growth factor seems to underlie the development of hemangiomas, disfiguring tumors arising early in life (pages 1236–1246).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
Investigational New Drugs Open Access 08 April 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chang, L.C. et al. Pediatrics 122, 360–367 (2008).
Jinnin, M. et al. Nat. Med. 14, 1236–1246 (2008).
Olsson, A.K., Dimberg, A., Kreuger, J. & Claesson-Welsh, L. Nat. Rev. Mol. Cell Biol. 7, 359–371 (2006).
Fong, G.H., Rossant, J., Gertsenstein, M. & Breitman, M.L. Nature 376, 66–70 (1995).
Hiratsuka, S., Minowa, O., Kuno, J., Noda, T. & Shibuya, M. Proc. Natl. Acad. Sci. USA 95, 9349–9354 (1998).
Ferrara, N. EXS 209–231 (2005).
Nanda, A. et al. Cancer Res. 64, 817–820 (2004).
Wang, H., Zhang, Y., Toratani, S. & Okamoto, T. Oncogene 23, 8700–8704 (2004).
Eklund, L. & Olsen, B.R. Exp. Cell Res. 312, 630–641 (2006).
North, P.E., Waner, M., Mizeracki, A. & Mihm, M.C., Jr. Hum. Pathol. 31, 11–22 (2000).
Khan, Z.A. et al. J. Clin. Invest. 118, 2592–2599 (2008).
Kamba, T. & McDonald, D.M. Br. J. Cancer 96, 1788–1795 (2007).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Claesson-Welsh, L. Healing hemangiomas. Nat Med 14, 1147–1148 (2008). https://doi.org/10.1038/nm1108-1147
Issue Date:
DOI: https://doi.org/10.1038/nm1108-1147
